Regulation on Health Technology Assessment (HTA)

Author
Published on
Category

The EU has taken a significant step to enhance the availability of innovative health technologies, including groundbreaking medicines and specific medical devices, for EU patients. This initiative is fuelled by a commitment to efficient resource utilization, heightened quality in HTA across the EU, and the enhancement of business predictability.
Key Dates:

Regulation (EU) 2021/2282  became effective on January 11, 2022.
Application of the regulation begins on January 12, 2025.

Why is this important? Major changes are on the horizon for the reimbursement of new medicines, and the EU has crafted a dynamic  rolling plan for the Implementation of the Regulation on HTA.
Stay Informed: In collaboration with national HTA agencies, the EU and EU HTA have organized a series of regional information events spanning 2023 and 2024. These events keep you abreast of crucial updates and changes.
Save the Date: Tuesday, 30 January 2024 ⏰ Time: 9:00 – 12:30 CET
Given the introduction of the new Joint Clinical Assessment procedure (JCA), which will be mandatory, staying informed is paramount. To be ready for these changes, mark your calendar for the event on January 30, 2024.
Where to Find More Information: Follow the EU dedicated HTA website  and our further posts to delve into the details of the new HTA re-regulation and understand its impact on your daily practice.

Explore more Updates

Windsor Framework – Changes to the licensing of medicines for human use in the UK (and affecting Northern Ireland)

Unlocking Innovation with EMA’s Innovation Task Force

The International Recognition Procedure (IRP) for Medicinal Products in the UK

Valentyna Starodub
Founder and Chief Executive Officer

Let's Connect

Talk to an expert